Calcitonin; Related Peptides Patents (Class 530/307)
-
Patent number: 11541123Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.Type: GrantFiled: December 17, 2021Date of Patent: January 3, 2023Assignee: Eli Lilly and CompanyInventors: Tamer Coskun, Hongchang Qu
-
Patent number: 10603305Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.Type: GrantFiled: March 19, 2018Date of Patent: March 31, 2020Assignee: Upsher-Smith Laboratories, LLCInventors: Rajesh Gandhi, Sreekanth Manikonda, Arun Jana, Sameer Shrinivas Kunte
-
Patent number: 9862754Abstract: Provided herein are peptides, that in combination with metformin, are effective for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of appetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test in synergistic combination with metformin. The peptides are selected from sequences SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.Type: GrantFiled: October 1, 2016Date of Patent: January 9, 2018Assignee: KeyBioscience AGInventors: Nozer M. Mehta, William Stern, Amy M. Sturmer, Morten Asser Karsdal, Kim Henriksen
-
Patent number: 9193776Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an ?-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.Type: GrantFiled: January 25, 2013Date of Patent: November 24, 2015Inventor: Christopher J. Soares
-
Publication number: 20140329752Abstract: The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide.Type: ApplicationFiled: January 25, 2013Publication date: November 6, 2014Inventor: Christopher J. Soares
-
Publication number: 20140249076Abstract: Provided herein are amylin-calcitonin peptide conjugates having enhanced duration of biological activity, and methods of use thereof. The amylin-calcitonin peptide conjugates include duration enhancing moieties, such as water soluble polymers and long chain aliphatic groups, bound to the amylin-calcitonin peptide. Methods of use are provided for treatment of an eating disorder, insulin resistance, obesity, overweight, abnormal postprandial hyperglycemia, Type I diabetes, Type II diabetes, gestational diabetes, metabolic syndrome, dumping syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, cancer, pulmonary hypertension, cholescystitis or osteoarthritis.Type: ApplicationFiled: October 17, 2012Publication date: September 4, 2014Inventors: Manoj P. Samant, Ved Srivastava, Odile Esther Levy, Christine M. Mack, William E. Rote
-
Publication number: 20140235789Abstract: The present application discloses peptides and peptaibols of high purity may be obtained by solid phase peptide synthesis using as the starting resin hydroxy amino acids, hydroxy amino acid amides, hydroxy amino alcohols or small peptides containing hydroxy amino acids attached to polymers through their side chain.Type: ApplicationFiled: February 21, 2013Publication date: August 21, 2014Applicant: Chemical & Biopharmaceutical Laboratories of Patras S.A.Inventor: Chemical & Biopharmaceutical Laboratories of Patras S.A.
-
Patent number: 8765675Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: GrantFiled: June 21, 2010Date of Patent: July 1, 2014Assignee: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 8748383Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.Type: GrantFiled: April 15, 2013Date of Patent: June 10, 2014Assignees: Novartis AG, Emisphere Technologies, Inc.Inventors: Shoufeng Li, Anasuya Ashok Ghosh, Simon D. Bateman, Moise Azria, Alan E. Royce
-
Patent number: 8598120Abstract: The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.Type: GrantFiled: February 1, 2012Date of Patent: December 3, 2013Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LPInventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David G. Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine M. Mack, Qing Lin
-
Patent number: 8513188Abstract: This invention relates to the use of a cyclic compound of formula (I) wherein A, B independently in each occurrence is alkane-i,j-diyl having k carbon atoms, i and independently j being less than or equal k and k being selected from 1 to 10, wherein said alkane-i,j-diyl (i) may comprise one or more double bonds; (ii) is optionally substituted; and/or (iii) comprises a cycle, wherein the total number of cycles being cyclic sugars in said compound is selected from 0 to 4 and is less than p·(n+m); X,Y independently in each occurrence is a biocompatible functional group comprising at least one oxygen atom or two sulphur atoms; n, m independently of each other are selected from 0 to 20; p is selected from 1 to 10; n+m is equal or greater than 1; and p·(n+m) is selected from 3 to 30; wherein said compound is capable of forming a complex with a protonated primary and/or protonated secondary amino group and/or a protonated guanidinium group for the manufacture of a pharmaceutical or diagnostic composition.Type: GrantFiled: September 27, 2007Date of Patent: August 20, 2013Inventor: Paolo Botti
-
Patent number: 8497347Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: July 9, 2012Date of Patent: July 30, 2013Assignee: UGP Therapeutics, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20130165624Abstract: Compounds which can include an active (drug) moiety have the general formula (I): wherein: SA is a pentapeptide aa1-aa2-aa3-aa4-aa5, wherein at least one of aa1, aa2, aa3, aa4, and aa5 is L, I, E, D, and I, respectively, wherein L, I, E, and D are eponymous amino acids; SB is a dipeptide aa6-aa7, wherein at least one of aa6 and aa7 is L and W, respectively, wherein W and L are eponymous amino acids; R1 and R5 are N-, and C-terminal moieties, respectively; R3 and R4 are independently a linker selected from a substituted or unsubstituted methylene, an amino acid, a peptide, and a peptide bond; and S is a scaffold moiety, a bond, a peptide bond, an amino acid, or a peptide of up to three residues, wherein R3, S, and R4 together form a turn in the compound, and the compound selectively binds a serum albumin.Type: ApplicationFiled: December 22, 2012Publication date: June 27, 2013Applicant: SRI INTERNATIONALInventor: Hendrik Mario Geysen
-
Patent number: 8435946Abstract: Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.Type: GrantFiled: June 4, 2008Date of Patent: May 7, 2013Assignees: Novartis AG, Emisphere Technologies, Inc.Inventors: Shoufeng Li, Anasuya A Ghosh, Simon D Bateman, Moise Azria, Alan E Royce
-
Patent number: 8410052Abstract: The invention is directed to a method of administering pharmaceutical compositions comprising peptide drugs such as a calcitonin in combination with one or more oral delivery agents, together with an amount of a liquid, and method of treatment of disorders responsive to the action of peptide drugs such as a calcitonin employing such method of administration so as to enhance the oral bioavailability of a calcitonin. The methods of the invention increase the oral absorption and systemic bioavailability of peptide drugs, such as a calcitonin.Type: GrantFiled: February 29, 2008Date of Patent: April 2, 2013Assignee: Novartis AGInventor: Yatindra Joshi
-
Publication number: 20130071431Abstract: The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: Stabilitech Ltd.Inventor: Stabilitech Ltd.
-
Patent number: 8394767Abstract: The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.Type: GrantFiled: January 10, 2011Date of Patent: March 12, 2013Assignee: University of RochesterInventors: Ian M. Dickerson, Edward B. Brown
-
Publication number: 20130040884Abstract: Novel polypeptide derivatives having protracted profile of action.Type: ApplicationFiled: March 22, 2012Publication date: February 14, 2013Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
-
Publication number: 20120245083Abstract: Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments.Type: ApplicationFiled: October 27, 2010Publication date: September 27, 2012Applicant: Novo Nordisk A/SInventors: Anette Sams Nielsen, Thomas Kruse, Janos Tibor Kodra, Jesper F. Lau, Jacob Kofoed, Kirsten Raun, Cecilia Nilsson
-
Patent number: 8222298Abstract: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2-propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.Type: GrantFiled: November 25, 2011Date of Patent: July 17, 2012Assignee: CHU Sainte-JustineInventors: Alain Moreau, Genevieve Mailhot
-
Publication number: 20120164127Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: March 9, 2010Publication date: June 28, 2012Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey, Gregory Frost
-
Publication number: 20120142586Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: November 14, 2011Publication date: June 7, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 8133505Abstract: The present invention provides a system for transdermal delivery of dried or lyophilized pharmaceutical compositions and methods using thereof. The system comprises an apparatus for facilitating transdermal delivery of an agent that generates hydrophilic micro-channels, and a patch comprising a therapeutically active agent. The present invention is useful for transdermal delivery of hydrophilic agents, particularly of high molecular weight proteins.Type: GrantFiled: January 21, 2009Date of Patent: March 13, 2012Assignee: TransPharma Medical Ltd.Inventors: Meir Stern, Galit Levin
-
Publication number: 20120059145Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.Type: ApplicationFiled: August 31, 2011Publication date: March 8, 2012Applicant: University of Georgia Research Foundation, Inc.Inventor: Elliot ALTMAN
-
Publication number: 20120045816Abstract: Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.Type: ApplicationFiled: July 14, 2011Publication date: February 23, 2012Inventors: Darius Ghaderi, Ajit Varki
-
Publication number: 20120039843Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).Type: ApplicationFiled: September 8, 2011Publication date: February 16, 2012Applicant: N.V. OrganonInventors: Ebo Sybren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
-
Patent number: 8114958Abstract: The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.Type: GrantFiled: February 11, 2005Date of Patent: February 14, 2012Assignee: Amylin Pharmaceuticals, Inc.Inventors: Christopher J. Soares, Michael R. Hanley, Diana Y. Lewis, David Geoffrey Parkes, Carolyn M. Jodka, Kathryn S. Prickett, Soumitra S. Ghosh, Christine Marie Mack, Qing Lin
-
Publication number: 20120003712Abstract: The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be desirably employed in the development of long acting formulations of various peptide drugs having high in-vivo activity and markedly prolonged in-blood half-life.Type: ApplicationFiled: March 18, 2010Publication date: January 5, 2012Applicant: HANMI HOLDINGS CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Jae Min Lee, Young Kyung Park, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 8076291Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: January 22, 2010Date of Patent: December 13, 2011Assignee: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 8030269Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: GrantFiled: October 27, 2009Date of Patent: October 4, 2011Assignee: Biocon LimitedInventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
-
Publication number: 20110236412Abstract: A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 ?M or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.Type: ApplicationFiled: September 24, 2009Publication date: September 29, 2011Applicant: Stabilitech Ltd.Inventor: Jeffrey Drew
-
Publication number: 20110189205Abstract: The present invention is directed to methods of treating cancer and preventing cancer metastasis in a subject by administering a modulator of CGRP receptor signaling. The present invention is further directed to methods of identifying novel compounds that inhibit CGRP receptor signaling, and reagents and animal models useful for the same.Type: ApplicationFiled: January 10, 2011Publication date: August 4, 2011Applicant: UNIVERSITY OF ROCHESTERInventors: Ian M. Dickerson, Edward B. Brown
-
Publication number: 20110112990Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.Type: ApplicationFiled: November 9, 2010Publication date: May 12, 2011Applicants: The Regents of the University of Colorado, a body corporate, AmideBio LLCInventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
-
Publication number: 20110034385Abstract: The present invention provides a supramolecular protein assembly useful as a protein therapeutics for the treatment of metabolic disorders particularly diabetes. The supramolecular protein assembly disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising supramolecular protein assembly. The composition disclosed in the present invention particularly comprises supramolecular insulin assembly.Type: ApplicationFiled: October 13, 2008Publication date: February 10, 2011Applicants: NATIONAL INSTITUTE OF IMMUNOLOGY, INDIAN INSTITUTE OF SCIENCEInventors: Avadhesha Surolia, Sarika Gupta, Mahendra Singh, Tandrika Chattopadhyay
-
Publication number: 20110020273Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the bispecific immunocytokine DNL construct comprises an IgG antibody attached to a Fab antibody fragment and a cytokine, wherein the IgG and the Fab bind to different target antigens which may be expressed on the same target cell. The bispecific immunocytokine DNL construct exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or even other types of cytokine-antibody DNL constructs. In a most preferred embodiment the construct comprises an anti-CD20 IgG antibody conjugated to an anti-HLA-DR Fab and IFN?2b, although other combinations of antibodies, antibody fragments and cytokines may be used to form the subject DNL complexes.Type: ApplicationFiled: August 27, 2010Publication date: January 27, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20100311650Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: January 22, 2010Publication date: December 9, 2010Applicant: UNIGENE LABORATORIES INC.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 7812120Abstract: Compositions suitable for intranasal administration containing calcitonin, chlorobutanol, a pH of about 3.5, and sodium chloride, and an intranasal spray and a pharmaceutical delivery device thereof.Type: GrantFiled: March 22, 2004Date of Patent: October 12, 2010Assignee: Par Pharmaceutical, Inc.Inventors: Steven C. Quay, Jorge C. de Meireles, Arati A. Deshpande, Zenaida O. Go, Anthony P. Sileno
-
Publication number: 20100254943Abstract: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.Type: ApplicationFiled: November 2, 2009Publication date: October 7, 2010Applicant: ALLOZYNE, INC.Inventors: Kenneth H. Grabstein, Aijun Wang, Natalie Winblade Nairn, Thomas James Graddis, Stephen McCraith, Deepshikha Datta
-
Publication number: 20100240865Abstract: The invention relates to methods for the preparation of polypeptides. The polypeptides are prepared in high purity of at least about 98.5%, and preferably at least about 99% by HPLC.Type: ApplicationFiled: February 4, 2010Publication date: September 23, 2010Inventors: Avi Tovi, Chaim Eidelman, Shimon Shushan, Shai Elster, Hagi Alon
-
Publication number: 20100233783Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.Type: ApplicationFiled: March 23, 2006Publication date: September 16, 2010Applicant: Straumann Holding AGInventors: Johan Per Henrik Svensson, Leif Bülow
-
Publication number: 20100227815Abstract: The present invention relates to site-specific PEGylated linear salmon calcitonin analogues, or pharmaceutically acceptable salts thereof, process for their preparation, pharmaceutical compositions comprising them, and their use for the preparation of a medicament for the treatment or prevention of diseases associated with bone metabolism, e.g., osteoporosis.Type: ApplicationFiled: June 4, 2008Publication date: September 9, 2010Applicant: Institute of Pharmacology and Toxicology Academy Of Military Medical ScienceInventors: Keliang Liu, Jiankun Qie, Zhixia Yang, Yuanjun Liang, Ying Wang, Zehui Gong, Huajin Dong
-
Publication number: 20100204116Abstract: The present invention is directed to the use of the peptide compound Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-Nh2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: ApplicationFiled: September 9, 2008Publication date: August 12, 2010Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Patent number: 7749954Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: GrantFiled: July 22, 2004Date of Patent: July 6, 2010Assignee: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 7745216Abstract: The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.Type: GrantFiled: May 27, 2004Date of Patent: June 29, 2010Assignee: Curis, Inc.Inventors: Kevin Pang, Kuanghui Lu
-
Publication number: 20100160209Abstract: The invention provides for a cell permeable peptide conjugated to an insulin compound for improved cell penetration of the insulin moiety. The composition may be delivered by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means for the treatment, including prophylaxis of Type I, Type II diabetes, prediabetes and/or metabolic syndrome.Type: ApplicationFiled: May 10, 2007Publication date: June 24, 2010Applicant: SmithKline Beecham CorporationInventors: Dany Doucet, Mickey Lee Wells
-
Patent number: 7713932Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: GrantFiled: November 8, 2002Date of Patent: May 11, 2010Assignee: Biocon LimitedInventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
-
Publication number: 20100105624Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: ApplicationFiled: October 27, 2009Publication date: April 29, 2010Inventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan
-
Patent number: 7658917Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: June 17, 2003Date of Patent: February 9, 2010Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Ethan R. Signer, James Wakefield, Laura Kasman, Gary Musso, Michael J. Reed
-
Publication number: 20090286723Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.Type: ApplicationFiled: August 11, 2006Publication date: November 19, 2009Applicant: AMYLIN PHARMACEUTICALS, INC.Inventors: Odile Esther Levy, Michael R. Hanley, Carolyn M. Jodka, Diana Y. Lewis, Christopher J. Soares, Soumitra S. Ghosh, Lawrence J. D'Souza, David G. Parkes, Christine M. Mack, Behrouz Bruce Forood
-
Patent number: 7608584Abstract: Calcitonin drug-oligomer conjugates that include a calcitonin drug coupled to an oligomer including a single polyalkylene glycol moiety consisting of between 4 and 10 polyalkylene glycol subunits are disclosed. Pharmaceutical compositions including such conjugates and methods of treating bone disorders by administering such conjugates are also disclosed.Type: GrantFiled: November 8, 2002Date of Patent: October 27, 2009Assignee: Biocon LimitedInventors: Nnochiri N. Ekwuribe, Balasingam Radhakrishnan